Pharma deals indicate promise of RNAi therapeutics

07/24/2008 | InPharm.com

Novartis has extended its collaboration with Alnylam Therapeutics and Roche has purchased gene-silencing specialist Mirus Bio Corp., an indication that the drug industry recognizes the research and commercial possibilities in RNAi-based therapeutics for a range of diseases. A Novartis official said RNAi "holds great potential," adding, "In particular, this new area of biology has potential to treat diseases that have not been able to be addressed by traditional approaches."

View Full Article in:

InPharm.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY